Zeta Biotech get listed on Euronext’s Marché Libré

Zeta Biotech, which specialises in products for the separation of molecules through the use of gel electrophoresis, is raising about €1 million with an initial public offering of 206,065 shares on the Euronext’s Marché Libré in Paris.

Shire acquires rights to experimental anti-scarring treatment

Shire Plc has agreed to pay up to $825 million for an experimental drug for the prevention and reduction of scarring in connection with surgery. The licensing agreement, with Renovo Group Plc, would give Shire exclusive rights to market the drug, called Juvista, in every country except the member states of the European Union.

Charities can fund businesses, says Wellcome Trust officer

There are a growing number of instances where charitable organisations can provide money to profit-making companies and still demonstrate that they are working in the public interest, according Richard Seabrook, head of business development at the Wellcome Trust.

AMT's IPO sells well

Amsterdam Molecular Therapeutics AMT Holding NV, which develops gene-based therapies for orphan diseases, raised €50 million in an initial public offering on the Euronext Amsterdam stock exchange.